P

Paratek Pharmaceuticals Inc
F:N4CN

Watchlist Manager
Paratek Pharmaceuticals Inc
F:N4CN
Watchlist
Price: 2.024 EUR Market Closed
Market Cap: 115.9m EUR

Relative Value

There is not enough data to reliably calculate the relative value of N4CN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

N4CN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0.7
Median 5Y
0.8
Industry
2.6
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
21.7
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-4.7
Industry
16.7
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.1
Industry
23.1
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.7
Industry
2.2
vs History
vs Industry
Median 3Y
1.9
Median 5Y
2
Industry
2.9
vs History
vs Industry
Median 3Y
2.3
Median 5Y
2.3
Industry
5.5
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
13.2
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.6
Industry
16.8
vs History
vs Industry
Median 3Y
-14.7
Median 5Y
-11.8
Industry
15.9
vs History
vs Industry
Median 3Y
-14.7
Median 5Y
-11.8
Industry
19.2
vs History
vs Industry
Median 3Y
3.4
Median 5Y
3.5
Industry
1.9

Multiples Across Competitors

N4CN Competitors Multiples
Paratek Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Paratek Pharmaceuticals Inc
F:N4CN
115.9m EUR 0.8 -2.2 -8 -7.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.3B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
262.9B CHF 4.3 27.9 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP 4.9 30.6 108.9 159.3
CH
Novartis AG
SIX:NOVN
212.1B CHF 4.8 18.7 11.9 15.3
US
Merck & Co Inc
NYSE:MRK
260.5B USD 4.1 13.7 9.7 11.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 14.6 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
P
Paratek Pharmaceuticals Inc
F:N4CN
Average P/E: 24.3
Negative Multiple: -2.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.6
38%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
P
Paratek Pharmaceuticals Inc
F:N4CN
Average EV/EBITDA: 439
Negative Multiple: -8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
9.7
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
P
Paratek Pharmaceuticals Inc
F:N4CN
Average EV/EBIT: 1 881.5
Negative Multiple: -7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.5
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3